{
    "key_points": [
        "WHO validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use.",
        "This validation assures the vaccine meets international standards for safety, efficacy, and manufacturing.",
        "Dr Mari\u00e2ngela Sim\u00e3o, WHO Assistant-Director General, emphasized the need for multiple COVID-19 vaccines to address global access inequity.",
        "Emergency Use Listing (EUL) by WHO is a prerequisite for COVAX Facility vaccine supply and international procurement.",
        "The WHO assessment of the Sinovac-CoronaVac vaccine included on-site inspections of its production facility.",
        "The vaccine is suitable for low-resource settings due to its easy storage requirements.",
        "The WHO recommends the vaccine for adults 18 years and older, with a two-dose schedule.",
        "Vaccine efficacy results showed it prevented symptomatic disease in 51% of recipients and severe COVID-19 and hospitalization in 100% of the studied population.",
        "While efficacy in older adults (over 60 years) could not be estimated from trials, the WHO does not recommend an upper age limit due to supportive data.",
        "The EUL process assesses novel health products during public health emergencies, focusing on safety, efficacy, and quality."
    ],
    "spokespersons": [
        "Dr Mari\u00e2ngela Sim\u00e3o (Assistant-Director General for Access to Health Products, WHO)"
    ],
    "article_type": "government agency statement",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}